Scinai Immunotherapeutics Ltd.
SCNI
$1.13
-$0.14-11.02%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 0.00% | 87.62% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.00% | 87.62% | |||
| Cost of Revenue | 0.00% | 173.86% | |||
| Gross Profit | 0.00% | -280.24% | |||
| SG&A Expenses | 0.00% | -17.26% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.00% | -8.14% | |||
| Operating Income | 0.00% | 16.86% | |||
| Income Before Tax | 0.00% | 7.31% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 0.00% | 7.31% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 0.00% | 7.31% | |||
| EBIT | 0.00% | 16.86% | |||
| EBITDA | 0.00% | 13.29% | |||
| EPS Basic | 0.00% | 77.15% | |||
| Normalized Basic EPS | 0.00% | 90.55% | |||
| EPS Diluted | 0.00% | 77.15% | |||
| Normalized Diluted EPS | 0.00% | 90.55% | |||
| Average Basic Shares Outstanding | 0.00% | 28.76% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||